Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1 Dose Escalation And Randomized Expansion Study Of The Safety, Tolerability, And Pharmacokinetics Of MT-125 Monotherapy With Radiation In Patients With Newly Diagnosed Glioblastoma
Jacksonville, Fla.,
Rochester, Minn.
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard of care treatment.
Initially, participants with newly diagnosed glioblastoma will be given different doses of MT-125 in combination with radiotherapy (RT) with the goal of identifying the highest tolerated dose.
Up to 36 people with glioblastoma who are at least18 years old are being invited to join this study. MT-125 is a type of study treatment which acts on cancer cells in the brain to destroy them. It will be administered on the same day as your standard of care radiotherapy because it is also designed to help radiotherapy work better. However, this is the first time MT-125 will be studied in humans. Therefore, the use is considered investigational. If you would like more details about MT-125 in glioblastoma participants, please ask the Study Doctor.
You will be among the first participants with glioblastoma to receive this study treatment. Its safety and effectiveness have not yet been established in humans. Thus, we do not know whether it will work for you. Your condition may improve, may get worse, or there may be no change.
The selected participant population-individuals newly diagnosed with histologically and/or molecularly confirmed IDH wild-type, MGMT-unmethylated glioblastoma-represents those least likely to experience safety concerns or adverse events related to the study treatment, and most likely to derive therapeutic benefit.
There are certain tests/questions you must complete to find out if you meet the requirements to be in the study. If you do not meet these requirements, you cannot take part in the study. If this happens, you can talk to your Study Doctor about other options.
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Optune® (TTFields, 200 KHz) Concomitant With Maintenance Temozolomide And Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide And Placebo For The Treatment Of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58).
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
-
MC230713 Neuro-Oncology Anywhere: Deploying Mayo Clinic’s remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation (Neuro-Oncology Anywhere)
Rochester, Minn.
The purpose of this study is to determine the feasibility of completing serial remote cognitive, activity/sleep, and selfreport assessments in clinical trial participants who have previously received cranial radiation.
-
MC240703: Neuro-Oncology Anywhere: Glioma Home-Based Sequential Therapy (GHoST) Protocol
Jacksonville, Fla.,
Rochester, Minn.
This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.
-
Patient and caregiver priorities in neuro-oncology care
Rochester, Minn.
The purpose of this study is to conduct semi-structured interviews with patients who have primary and metastatic CNS tumors as well as caregivers of these patients.
-
Voices: Messages Of Wisdom And Hope In The Face Of Illness
Rochester, Minn.
The purpose pf this study is to see change in patient dignity impact scale scores prior to and after completion of patient and caregiver recordings.
Contact Us for the Latest Status
-
A Phase 1 Dose Escalation And Randomized Expansion Study Of The Safety, Tolerability, And Pharmacokinetics Of MT-125 Monotherapy With Radiation In Patients With Newly Diagnosed Glioblastoma
Scottsdale/Phoenix, Ariz.
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard of care treatment.
Initially, participants with newly diagnosed glioblastoma will be given different doses of MT-125 in combination with radiotherapy (RT) with the goal of identifying the highest tolerated dose.
Up to 36 people with glioblastoma who are at least18 years old are being invited to join this study. MT-125 is a type of study treatment which acts on cancer cells in the brain to destroy them. It will be administered on the same day as your standard of care radiotherapy because it is also designed to help radiotherapy work better. However, this is the first time MT-125 will be studied in humans. Therefore, the use is considered investigational. If you would like more details about MT-125 in glioblastoma participants, please ask the Study Doctor.
You will be among the first participants with glioblastoma to receive this study treatment. Its safety and effectiveness have not yet been established in humans. Thus, we do not know whether it will work for you. Your condition may improve, may get worse, or there may be no change.
The selected participant population-individuals newly diagnosed with histologically and/or molecularly confirmed IDH wild-type, MGMT-unmethylated glioblastoma-represents those least likely to experience safety concerns or adverse events related to the study treatment, and most likely to derive therapeutic benefit.
There are certain tests/questions you must complete to find out if you meet the requirements to be in the study. If you do not meet these requirements, you cannot take part in the study. If this happens, you can talk to your Study Doctor about other options.
-
Voices: Messages Of Wisdom And Hope In The Face Of Illness
Jacksonville, Fla.
The purpose pf this study is to see change in patient dignity impact scale scores prior to and after completion of patient and caregiver recordings.
Closed for Enrollment
-
MC240703: Neuro-Oncology Anywhere: Glioma Home-Based Sequential Therapy (GHoST) Protocol
Scottsdale/Phoenix, Ariz.
This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.
-
Neuro-Oncology Anywhere 242: Pilot Study Evaluating Telehealth and In-person Assessments in Patients with Glioma Receiving Oral Chemotherapy
Rochester, Minn.
The purpose of this study is to evaluate the safety, feasibility and acceptability of telehealth assessments for patients with GBM receiving oral chemotherapy.
.